Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of LIPUM.ST is 16 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell